Thanks to the HCV Advocate for the following information:

Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EASL
http://hcvadvocate.blogspot.com/2011/04 ... -data.html
Apr 4

Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
http://hcvadvocate.blogspot.com/2011/04 ... ve-12.html
Apr 4

Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment
http://hcvadvocate.blogspot.com/2011/04 ... t-svr.html
Apr 3

Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio:
FDA Fast Track designations granted for both: the protease inhibitor BI 201335 plus standard-of-care and the interferon-free combination of BI 201335 with polymerase inhibitor, BI 207127
http://hcvadvocate.blogspot.com/2011/04 ... tis-c.html
Apr 2

PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
http://hcvadvocate.blogspot.com/2011/04 ... erior.html
Apr 2

EASL 2011 Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients atEASL 2011
http://hcvadvocate.blogspot.com/2011/04 ... -data.html
Apr 2

New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response
http://hcvadvocate.blogspot.com/2011/04 ... relis.html
Apr 1

First Vaccine For Viral Hepatitis C Could Become A Reality
http://hcvadvocate.blogspot.com/2011/04 ... tis-c.html
Apr 1

Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
http://hcvadvocate.blogspot.com/2011/04 ... sents.html
Apr 1

EASL 2011 Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
http://hcvadvocate.blogspot.com/2011/04 ... -with.html
Apr 1

Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL
http://hcvadvocate.blogspot.com/2011/04 ... -from.html
Apr 1

OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced rates of depression in HCV patients treated with Locteron
http://hcvadvocate.blogspot.com/2011/03 ... phase.html
Mar 31

Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination with Pegylated Interferon-Alpha and Ribavirin
http://hcvadvocate.blogspot.com/2011/03 ... titis.html
Mar 31

Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows
http://hcvadvocate.blogspot.com/2011/03 ... viral.html
Mar 31

http://www.hcvadvocate.org/news/EASL_2011.html

---

Add this page to your favourite Social Bookmarking websites;

Set as favorite

Email this

Hits: 592

Comments (0)

Write comment

Name

Email

Comment

smaller | bigger

Subscribe via email (registered users only)

I have read and agree to the Terms of Usage.

Add Comment